Abbott Laboratories agreed to develop a fluorescence in situ hybridization-based companion diagnostic to determine which patients will benefit from ibrutinib, an experimental chronic lymphocytic leukemia drug being developed by Pharmacyclics and Johnson & Johnson's Janssen Biotech. The test will identify high-risk CLL patients with a deletion in chromosome 17p.

Related Summaries